We provide independent research and advice that helps companies communicate with investors. Find out what we do >
The reassurance of a Recognised Investment Exchange: The Financial Conduct Authority (FCA) approved IPSX in January 2019 after a long process that included examination of IPSX’s infrastructure, trading and settlement processes, and outsourced partners. Wide appeal: The fractional ownership of ‘quasi-direct property’ through IPSX will attract the widest range of investors, e.g. retail investors will […]
Important information This feature article has not been commissioned by AstraZeneca. It has been prepared purely for informational purposes, and is not a recommendation to readers to buy or sell AZN shares. As Hardman & Co does not trade in shares, this article is not an inducement and is, therefore, MiFID II compliant.
We try to answer the questions of why to invest in a company and what the risks are in doing so. For many investors, simply having a deep discount to NAV is a good enough answer to the first question. However, investors need to appreciate the risks and, in particular, the reasons why the shares are at a discount. In this report, we examine the companies with the largest discounts and review those very issues.
Our deep sector knowledge and experience illuminates value for companies and brings clarity to investors.
We produce detailed and unbiased reviews into the latest tax enhanced products, for managers, advisers and investors.
Burford’s performance continues to reward long-term investors. Since engaging Hardman & Co, our shareholder base has widened, and liquidity has improved. We are pleased with these results and Hardman & Co’s help in getting us to where we are today
Elizabeth O'Connell, Chief Financial OfficerRead their story